Call me cynical, but this headline from yesterday's Washington Post strikes me as the week's winner for non-shocking news: "Comparison of Schizophrenia Drugs Often Favors Firm Funding Study." Turns out that, with a bit of tinkering here and there, a comparative drug trial can be (and often is) structured to stack the deck in favor of the company footing the bill. Wow. Who ever would have guessed such studies weren't entirely impartial? --Michelle

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.